Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

The management of chronic thromboembolic pulmonary hypertension has significantly changed over the last decade with the availability of both specific therapies and interventional treatments. In parallel, implantable pumps for intravenous administration of treprostinil have broadened the spectrum of...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Regina Steringer-Mascherbauer, Charlotte Huber, Uwe Fröschl, Dagmar Engleder, Reinhold Függer, Maria Lummersdorfer, Ralf Lenhard, Martin Martinek
Format:	Artykuł
Język:	English
Wydane:	MDPI AG 2023-07-01
Seria:	Journal of Cardiovascular Development and Disease
Hasła przedmiotowe:	chronic thromboembolic pulmonary hypertension implantable pump intravenous treprostinil
Dostęp online:	https://www.mdpi.com/2308-3425/10/8/318

Podobne zapisy

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
od: Pavel Jansa, i wsp.
Wydane: (2023-07-01)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
od: Regina Steringer-Mascherbauer, i wsp.
Wydane: (2020-11-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
od: John W. Swisher, PhD, MD, i wsp.
Wydane: (2017-01-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
od: Jan C. Kamp, i wsp.
Wydane: (2021-05-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
od: Marcin Kurzyna, i wsp.
Wydane: (2017-12-01)

Venoarterial extracorporeal membrane oxygenation for vasoplegic shock after treprostinil refill of an implanted intravenous pump: a case report
od: Lucía Valencia, i wsp.
Wydane: (2024-01-01)

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure
od: Xiaofeng Wang, i wsp.
Wydane: (2024-10-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
od: Julia McSweeney, i wsp.
Wydane: (2023-04-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
od: Lianghua Xiao, i wsp.
Wydane: (2024-09-01)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
od: Ibrahim Alissa, i wsp.
Wydane: (2023-04-01)

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia
od: Felix Rafael De Bie, i wsp.
Wydane: (2022-07-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
od: Piotr Kędzierski, i wsp.
Wydane: (2025-01-01)

Comparison of treprostinil and oral sildenafil for the treatment of persistent pulmonary hypertension of the newborn: a retrospective cohort study
od: Enhuan Wei, i wsp.
Wydane: (2023-11-01)

Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
od: Daniel Lachant, DO, i wsp.
Wydane: (2025-05-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
od: Nicholas S. Hill, i wsp.
Wydane: (2022-07-01)

Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function
od: Aleksandra Judina, i wsp.
Wydane: (2023-12-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
od: Aparna C. Swaminathan, i wsp.
Wydane: (2024-11-01)

BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
od: Leslie A. Spikes, i wsp.
Wydane: (2022-04-01)

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
od: Helena Gauani, i wsp.
Wydane: (2022-04-01)

Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report
od: Jacqueline Brewer, i wsp.
Wydane: (2023-06-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
od: Shelsey W. Johnson, i wsp.
Wydane: (2022-07-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
od: Garance Kopp, i wsp.
Wydane: (2020-10-01)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
od: Helena Gauani, i wsp.
Wydane: (2023-03-01)

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy
od: Donna Steinbacher, i wsp.
Wydane: (2024-04-01)

Renal infarction associated with low dose intravenous immunoglobulin in a kidney transplant recipient with sepsis: a case report and literature review
od: Eun Woo Choi, i wsp.
Wydane: (2021-10-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
od: N. V. Marukyan, i wsp.
Wydane: (2021-05-01)

Balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
od: N M Danilov, i wsp.
Wydane: (2019-04-01)

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review
od: Burger CD, i wsp.
Wydane: (2024-05-01)

Direct prostacyclin transition in pediatric patients with pulmonary hypertension
od: Kelly Merrill, i wsp.
Wydane: (2024-04-01)

Bilateral versus unilateral balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
od: Cheng Hong, i wsp.
Wydane: (2022-05-01)

Efficacy and safety of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension
od: Zheng-Wei Chen, i wsp.
Wydane: (2021-03-01)

Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation
od: Gil Bu Kang, i wsp.
Wydane: (2023-11-01)

Inoperable chronic thromboembolic pulmonary hypertension: Evolution of prognosis over 10 years of new emerging therapies
od: Diederik P. Staal, i wsp.
Wydane: (2024-07-01)

Sex-specific cardiopulmonary exercise testing indices to estimate the severity of inoperable chronic thromboembolic pulmonary hypertension
od: Chen TX, i wsp.
Wydane: (2018-01-01)

Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty
od: Qi Jin, i wsp.
Wydane: (2019-11-01)

Chronic Thromboembolic Pulmonary Hypertension and ChronicThromboembolic Pulmonary Disease
od: HUANG Shenshen, i wsp.
Wydane: (2023-01-01)

Congruency between clinician‐assessed risk and calculated risk of 1‐year mortality in patients with pulmonary arterial hypertension: A retrospective chart review
od: Amresh Raina, i wsp.
Wydane: (2024-10-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
od: Jenna M. Faircloth, i wsp.
Wydane: (2023-08-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
od: Jenna M. Faircloth, i wsp.
Wydane: (2023-03-01)

Perioperative thromboembolism prophylaxis in children – is it necessary?
od: Izabela Pągowska-Klimek
Wydane: (2020-08-01)